Clinical Practice Session
Proteinuria and Hypertension in Patients with Cancer
November 08, 2025 | 04:30 PM - 06:00 PM
Location: General Assembly C, Convention Center
Session Description
Many solid-organ and hematologic cancers are associated with proteinuria and hypertension as part of paraneoplastic glomerular diseases. In this session, experts discuss the paraneoplastic glomerular diseases associated with cancers and anticancer agents, the pathophysiology of proteinuria, and hypertension secondary to anticancer agents. Additionally, this session reviews the benefits of SGLT2 inhibitors and GLP-1 receptor agonists in the management of proteinuria; the role of complement activation in thrombotic microangiopathy (TMA); and the benefits of C5 inhibition in patients with cancer.
Learning Objective(s)
- List the various cancers and anticancer agents that potentially cause proteinuria and hypertension
- Describe the mechanisms that can lead to the development of proteinuria and hypertension in patients with cancer
- Evaluate the benefits of SGLT2 inhibitors and GLP-1 receptor agonists in managing proteinuria and hypertension in patients with cancer
- Explain the role of complement activation in TMA and hypertension, as well as the potential benefits of complement inhibition in patients with cancer
Learning Pathway(s)
- Onconephrology
- Hypertension and Cardiorenal Disorders
Moderators
Presentations
- Paraneoplastic Glomerular Diseases in Patients with Cancer Leading to Proteinuria and Hypertension
04:30 PM - 04:50 PM
- Management of Proteinuria in Patients with Cancer: Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists
04:50 PM - 05:10 PM
- Complement Activation in TMA and Potential Benefits of Complement Inhibition in Patients with Cancer
05:10 PM - 05:30 PM
- Managing the Pressure: Hypertension from Hormonal Therapies in Cancer
05:30 PM - 05:50 PM
- Q&A
05:50 PM - 06:00 PM